




**AGENIX LIMITED**

7 Durbell Street P.O. Box 391  
Acacia Ridge QLD 4110  
Australia  
Tel : +61 (0)7 3370 6396  
Fax : +61 (0)7 3370 6370  
Website : www.agenix.com



82-34639

~~SEC#82 5258~~

18 May 2006



06013932

US Securities and Exchange Commission  
Attention: Filing Desk  
450 Fifth Street NW  
WASHINGTON DC 20549  
USA

**SUPPL**

Dear Sir

**Re: Submission Under Rule 12g3-2(b) - Agenix Limited**

We refer to the attached announcement that was made to the Australian Stock Exchange on 17 May 2006.

We are providing a copy of the announcement by virtue of our requirements under Rule 12g3-2(b).

Yours sincerely

Tony Finn  
Joint Company Secretary

**PROCESSED**

**JUN 05 2006 E**

**THOMSON  
FINANCIAL**

dlw 6/2



17 May 2006

## UPDATE ON ANIMAL HEALTH TRANSACTION

Further to the announcements made on 7 April 2006 and 24 April 2006, Agenix today announced that IDEXX Laboratories, Inc. is the party to which it has assigned the intellectual property of its AGEN Animal Health business, as well as granting certain distribution rights for its animal health diagnostic products.

IDEXX Laboratories, Inc. is a worldwide leader in the development and commercialisation of innovative technology-based products and services for veterinary, food and water applications. Headquartered in Westbrook, Maine in the United States, IDEXX conducts operations through 40 locations around the world, and employs over 3,000 people in full and part-time positions.

**END**

**For more information, please contact:**

Mr Neil Leggett  
CEO and Managing Director  
Agenix Limited  
Ph: 61 7 3370 6300

**Agenix Limited [ASX: AGX, OTC (NASDAQ): AGXLY]** is a global health and biotechnology company based in Brisbane, Australia. The Company is focused on developing a pipeline of monoclonal antibody-based products.

Agenix's lead candidate is its high-technology ThromboView<sup>®</sup> blood clot-imaging agent, which is currently undergoing human trials. ThromboView<sup>®</sup> uses radiolabelled antibodies to locate blood clots in the body, and could revolutionise the US \$3 billion global clot diagnostic imaging market. ThromboView<sup>®</sup> is being developed with the assistance of the Federal Government through its START scheme.

Agenix employs 90 staff and sells human and animal products to more than 50 countries. ThromboView<sup>®</sup> is a registered trademark of AGEN Biomedical Ltd, a wholly owned subsidiary of Agenix Limited.

[www.agenix.com](http://www.agenix.com)